clinical trial · NCT05718323
Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC
ETOP IBCSG Partners Foundation·phase2·recruiting·n = 44
SCLC,Extensive StageSLFN11-positiveNiraparib
brief summary
RAISE is an international, multicentre, single-arm phase II trial. The trial treatment consists of the addition of niraparib, 200 mg orally once daily to anti-PD-L1 antibody maintenance. The primary objective of this trial is to assess the clinical efficacy of the addition of niraparib to anti-PD-L1 monoclonal antibody maintenance treatment in patients with SLFN11-positive ED-SCLC which has not progressed following standard first-line chemo-immunotherapy.
started
Dec 20, 2023
primary completion
Dec 1, 2026
completion
Jun 1, 2027
last updated
May 29, 2026
official title
A Single-arm Phase II Trial of the Addition of Niraparib to Anti-PD-L1 Antibody Maintenance in Patients With SLFN11-positive, Extensive-disease Small Cell Lung Cancer.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol